Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 268-276

  Czuczman, Myron ^a   Grillo Lopez A J ^a   White, C A ^a   Saleh, M ^a   Gordon, L ^a   LoBuglio, A F ^a   Jonas, C ^a   Klippenstein, D ^a   Dallaire, B ^a   Varns, C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOXORUBICIN; MONOCLONAL ANTIBODY; PARACETAMOL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; B CELL LYMPHOMA; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

EID: 0344766075     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.268     Document Type: Article

References (35)

1. Parker S, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. Landis S, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
3. Longo D, De Vita V, Jaffe E, et al: Lymphocytic lymphomas, in DeVita VT Jr, Hellman S, Rosenberg S (eds): Cancer: Principles & Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 1859-1927
4. Harris N, Jaffe E, Stein H, et al: Lymphoma classification proposal: Clarification. Blood 85:857-860, 1995
5. Anderson K, Bates M, Slaughenhoupt B, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984
6. Aisenberg A: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 13:2656-75, 1995
7. Rosenberg S, Berard C, Brown J, et al: National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage: The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112-2135, 1982
8. Lukes R, Collins R: Immunologic characterization of human malignant lymphomas. Cancer 34:1488, 1974
9. Krajewski S, Tanaka S, Takayama S, et al: Investigation of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53:4701-4714, 1993
10. Gribben J, Neuberg D, Freedman A, et al: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3457, 1993
11. Maloney D, Levy R, Miller R: Monoclonal anti-idiotype therapy of B-cell lymphoma. Biol Ther Cancer 2:1-10, 1992
12. Maloney D, Brown S, Czerwinski D, et al: Monoclonal antiidiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80:1502-1510, 1992
13. Reff M, Camer K, Chambers K, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
14. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
15. Maloney D, Liles T, Czerwinski D, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
16. Maloney D, Grillo-López A, White C, et al: IDEC-C2B8 (RituxanAB) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
17. Cabanillas F, Rodriguez V, Freireich E: Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin's lymphoma: A prognostic factor comparison of two regimens. Med Pediatr Oncol 4:321-331, 1978
18. McKelvey E, Gottlieb J, Wilson H, et al: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1976
19. Jones S, Grozea P, Miller T, et al: Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A Southwest Oncology Group Study. J Clin Oncol 3:1318-1324, 1985
20. Dana B, Dahlberg S, Nathwani B, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
21. Rodriguez V, Cabanillas F, Burgess M, et al: Combination chemotherapy ("CHOP-BleO") in advanced (non-Hodgkin's) malignant lymphoma. Blood 49:325-333, 1977
22. McLaughlin P, Fuller L, Velasquez, W, et al: Stage III follicular lymphoma: Durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 5:867-874, 1987
23. Sullivan K, Neiman P, Kadin M, et al: Combined modality therapy of advanced non-Hodgkin's lymphoma: An analysis of remission duration and survival in 95 patients. Blood 62:51-61, 1983
24. Rijlaarsdam J, Toonstra J, Meijer O, et al: Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: A clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol 14:549-555, 1996
25. Freedman A, Gribben J, Neuberg D, et al: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
26. Fisher R, Gaynor E, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
27. Meyer R, Browman G, Samosh M, et al: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386-2393, 1995
28. Brusamolino E, Bertini M, Guidi S, et al: CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: An interim report comparing efficacy and toxicity. Haematologica 73:217-222, 1988
29. Hoofnagle J, Dusheiko G, Schafer D, et al: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447-449, 1982
30. Lok A, Liang R, Chiu E, et al: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 100:182-188, 1991
31. Liang R, Lok A, Lai C, et al: Hepatitis B infections in patients with lymphomas. Hematol Oncol 8:261-270, 1990
32. Bonadonna G, Valagussa B: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
33. Uyl-de Groot C, Hagenbeek A, Verdonck L, et al: Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 16:463-470, 1995
34. Gribben J, Neuberg D, Barber M, et al: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83:3800-3807, 1994
35. Gribben J, Freedman A, Woo S, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-3280, 1991